Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ38224342 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ38224342/placebo one of six (6) single ascending doses (25 100 300 600 1250 or 2000 mg) of JNJ 38224342 or matching placebo up to four (4) additional cohorts consisting of healthy male volunteers may be added |
| 002 | EXPERIMENTAL | JNJ38224342/placebo multiple ascending oral doses (100 250 500 750 mg) of JNJ 38224342 or matching placebo administered for 14 consecutive days in healthy male or female volunteers.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added |
| 003 | EXPERIMENTAL | JNJ38224342 single oral 100mg dose of JNJ 38224342 as a solution versus a single oral dose of JNJ 38224342 as a capsule formulation with and without food in healthy male volunteers |
| 004 | EXPERIMENTAL | JNJ38224342/placebo multiple oral doses of JNJ38224342 or matching placebo administered for up to 14 consecutive days in male and female volunteers number of days dosed and actual dose levels food requirements and regimens will be determined based on the data from Parts 1 2 and 3. |
| Name | Type | Description |
|---|---|---|
| JNJ38224342 | DRUG | multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers |
| JNJ38224342/placebo | DRUG | up to four (4) additional cohorts consisting of healthy male volunteers may be added |
Inclusion Criteria: * Non-smokers * If male, willing to use an acceptable method of birth control for duration of study and for 90 days post study * Females must be post menopausal, surgically sterilized and cannot be pregnant or lactating (all parts of study) * Have a clinical history of allergic ...
JNJ38224342 is an investigational small molecule being studied for the treatment of Seasonal Allergic Rhinitis. It is in Phase 1 clinical development and has been evaluated in a completed clinical trial involving patients with seasonal allergies.
JNJ38224342 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 1 clinical development for Seasonal Allergic Rhinitis.
JNJ38224342 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and has completed one Phase 1 clinical trial for Seasonal Allergic Rhinitis.
JNJ38224342 has been studied in one completed clinical trial, NCT01054352, which explored the safety of single and multiple doses in healthy patients and patients with seasonal allergies. The trial enrolled 182 participants in Canada.
Yes, JNJ38224342 and JNJ-38224342 refer to the same investigational drug. The clinical trial NCT01054352 uses the name JNJ-38224342, while the drug is also referred to as JNJ38224342 in development records.